Type 1 Diabetes (T1D) Treatments

Find Type 1 Diabetes (T1D) Treatments

Generic Name

Semaglutide

Brand Names

Ozempic, Rybelsus, Wegovy

FDA approval date: September 20, 2019

Classification: GLP-1 Receptor Agonist

Form: Injection, Tablet

What is Ozempic (Semaglutide)?

RYBELSUS and OZEMPIC tablets are indicated: as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus., to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events. RYBELSUS and OZEMPIC tablets are glucagon-like peptide-1 receptor agonists indicated:, as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. , to reduce the risk of major adverse cardiovascular events in adults with type 2 diabetes mellitus who are at high risk for these events.

Approved To Treat

Top Global Experts

View All

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Tired of the same old research?

Check Latest Advances

Related Clinical Trials

Semaglutide for Smoking Cessation in Patients With Diabetes: A Pilot Randomized Controlled Trial

Enrollment Status: Recruiting

Publish Date: September 08, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

A Placebo-controlled Comparability Study to Compare Two Presentations of Cagrilintide for Weight Management in Participants With Overweight or Obesity

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Drug

Study Phase: Phase 3

Summary: The purpose of this clinical study is to look at how well a study medicine called cagrilintide helps people living with excess body weight to lose weight. Participants will either get cagrilintide, the active study medicine being tested or placebo, a medicine that has no active medicine in it. Which treatment participants get is decided by chance. Cagrilintide is a new medicine under development t...

A Study Investigating Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0721-8060 in Healthy Adult Participants Living With Overweight or Obesity

Enrollment Status: Recruiting

Publish Date: September 04, 2026

Intervention Type: Drug

Study Phase: Phase 1

Summary: The purpose of the study is to find out if NNC0721-8060 is safe and how it works in people living with overweight or obesity.

View All Clinical Trials